title: Antithrombin-α for the prophylaxis of venous thrombosis in congenital antithrombin deficiency.
abstract: ATryn(®) is a transgenically produced recombinant antithrombin (AT) concentrate licensed in Europe and the USA for the thromboprophylaxis of hereditary AT-deficient patients undergoing surgical procedures who are at a high risk of venous thromboembolism. It is also licensed, in the USA only, for prevention the of venous thromboembolism in association with delivery and the immediate post-partum period. ATryn is administered as a continuous intravenous infusion, with weight-adjusted loading and maintenance dosing regimens. Recombinant AT has an identical amino acid structure with minor glycosylation differences to endogenous AT. ATryn has a shorter half-life but an equivalent efficacy to that of plasma-derived AT concentrates in the prevention of venous thromboembolism in this rare distinct group with a high thrombotic risk. In addition, this recombinant product should be free from the risk of human viral or prion transmission.
authors.affiliation: Department of Haematology, Royal Infirmary, Castle Street, Glasgow, UK. andrew.fyfe@nhs.net
authors.forename: Andrew
authors.initials: A
authors.lastname: Fyfe
authors.forename: R Campbell
authors.initials: RC
authors.lastname: Tait
mesh_terms: D000818:Animals; D020152:Antithrombin III Deficiency / Q000188:drug therapy*; D058833:Antithrombin Proteins / Q000009:adverse effects / Q000172:deficiency* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D058833:Antithrombin Proteins; D011994:Recombinant Proteins